Title
OCE-205 Signals a Potential New Direction for Hepatorenal Syndrome-AKI, with Tolerability at the Center
Highlight
OCE-205, a selective vasopressin V1a receptor mixed agonist-antagonist, showed numerically higher rates of clinical improvement in hepatorenal syndrome-acute kidney injury (HRS-AKI) than placebo in a phase 2 randomized trial.
The drug was generally well tolerated, with bradycardia the most common adverse event and no reported ischemic events or treatment-related respiratory failure.
Because the trial was stopped early after terlipressin approval, the study was underpowered for definitive efficacy conclusions, but it supports further investigation of OCE-205 as a novel HRS-AKI therapy.
Background
Hepatorenal syndrome-acute kidney injury is one of the most serious complications of advanced cirrhosis. It reflects a functional, potentially reversible decline in kidney perfusion driven by severe circulatory dysfunction, splanchnic vasodilation, and intense activation of vasoconstrictor systems. Despite being labeled an acute kidney injury syndrome, HRS-AKI is fundamentally a consequence of advanced portal hypertension and systemic hemodynamic instability rather than primary structural kidney damage.
The condition is associated with high short-term mortality and often emerges in patients with decompensated cirrhosis, ascites, and progressive vasodilatory shock physiology. For clinicians, the therapeutic goal is to restore effective arterial blood volume, improve renal perfusion, and reverse the creatinine rise before the syndrome progresses to multi-organ failure or the need for urgent liver transplantation.
Current vasoconstrictor therapy has practical limitations. Terlipressin, a vasopressin analog, is approved in the United States for HRS-AKI, but its use is constrained by concerns about respiratory failure, ischemic complications, and the challenge of balancing efficacy with safety in a fragile population. This creates a meaningful unmet need for agents that can improve kidney function while minimizing excessive vasoconstriction and cardiopulmonary toxicity.
OCE-205 was developed to address that gap. It is described as a selective V1a receptor mixed agonist-antagonist with no V2 receptor activity. That pharmacologic profile is important. V1a receptor activity is associated with vasoconstriction, which is the mechanism clinicians want to exploit in HRS-AKI to improve arterial pressure and renal perfusion. In contrast, V2 receptor activity can promote water retention and hyponatremia, which are undesirable in cirrhosis. A selective V1a approach therefore aims to preserve the intended hemodynamic benefit while avoiding off-target water-retaining effects.
Study Design
This was a randomized, double-blind, placebo-controlled, dose-ranging phase 2 study conducted at 23 North American centers. Patients with HRS-AKI received a continuous infusion of OCE-205 at 8, 15, 30, or 50 µg/hr, or placebo.
The primary endpoint was time to confirmed clinical improvement, defined as serum creatinine (sCr) less than 1.5 mg/dL with at least an absolute reduction of 0.3 mg/dL or more, sustained for 2 days. This endpoint is clinically meaningful because it captures not just a transient laboratory change but a confirmed renal response consistent with reversal of the HRS-AKI episode.
A key contextual issue shaped the trial’s interpretation. After terlipressin received approval, the study was stopped early because equipoise was considered insufficient to justify continued placebo-controlled enrollment. That decision is understandable from an ethical standpoint, but it also means the trial does not provide the statistical certainty that a fully completed phase 2 study might have offered.
Baseline characteristics were broadly balanced but numerically favored placebo in some respects, reflecting the small sample size. OCE-205-treated patients (n=37) had a baseline sCr of 2.6 mg/dL and MELD score of 27.9, compared with 2.3 mg/dL and 25.8 in the placebo group. Alcohol-related cirrhosis was common in both groups, 51.4% versus 60.0%, consistent with the severe underlying liver disease typical of HRS-AKI trials.
Key Findings
The primary endpoint was met in 48.6% of patients receiving OCE-205 compared with 30.0% receiving placebo. Numerically, this favors active therapy, but the difference did not reach statistical significance. The log-rank p value was 0.48, and Bayesian analysis was also not significant. In practical terms, the trial suggests a possible renal benefit, but it cannot establish efficacy with confidence.
The investigators emphasize a “predictable, capped maximal efficacy,” a phrase that likely reflects the drug’s pharmacology and dose-response behavior. In other words, higher doses did not appear to produce uncontrolled toxicity, and the efficacy signal did not seem to escalate beyond a certain level. For HRS-AKI therapy, that is an attractive concept because the clinical challenge is often not whether vasoconstriction works in principle, but whether it can be delivered in a controlled manner without causing ischemia or respiratory compromise.
Safety findings were a major strength of the report. Bradycardia was the most common adverse event, occurring in 21.6% of OCE-205 recipients and 0% of placebo recipients. Importantly, most episodes were asymptomatic and required no intervention. No new or unexpected safety signals were identified. The study reported no events of ischemia and no treatment-related respiratory failure at any dose level.
This safety profile matters because it addresses one of the central concerns in treating HRS-AKI with vasoconstrictors: the risk that improving renal perfusion may come at the cost of excessive systemic vasoconstriction. Terlipressin has renewed attention to this trade-off, particularly in patients with hypoxemia, advanced ascites, or limited cardiopulmonary reserve. Against that backdrop, a V1a-selective agent that appears to avoid ischemic and respiratory toxicity deserves careful consideration.
It is also worth noting what the data do not show. The abstract does not report robust comparative effect sizes, confidence intervals, or detailed dose-by-dose response results, which would help clarify whether one dose range performed better than others. Without those data, it is difficult to know whether the mixed agonist-antagonist design produced a true pharmacodynamic advantage or whether the trial simply lacked the sample size to discriminate among dose levels. Similarly, the small placebo group limits the reliability of between-group comparisons.
Interpretation and Clinical Context
From a clinical standpoint, OCE-205 should be viewed as a promising mechanistic candidate rather than a practice-changing therapy. The result most relevant to clinicians is not that the trial proved superiority over placebo, but that the drug produced a plausible renal response signal without the safety liabilities that often complicate vasoconstrictor treatment in cirrhosis.
The choice of a selective V1a profile is biologically coherent. In HRS-AKI, the aim is to reverse pathologic vasodilation and improve effective arterial blood volume. By avoiding V2 activity, OCE-205 may reduce the risk of water retention and dilutional hyponatremia. The absence of ischemic events in this study is encouraging, though the sample size is too small to exclude rarer toxicities. Likewise, the bradycardia signal suggests pharmacologic activity and warrants monitoring, but the fact that these events were mostly asymptomatic is reassuring.
The early termination of the study is the most important limitation. Once terlipressin became available, continuing a placebo-controlled HRS-AKI trial became more ethically and operationally difficult. However, stopping early introduces the risk of an underpowered study with unstable estimates. The apparent difference between 48.6% and 30.0% could represent a real treatment effect, but it could also be due to chance or baseline imbalances in a very small sample.
Generalizability is another issue. The trial was conducted at North American centers and involved a relatively small cohort. The findings may not fully apply to patients with very advanced circulatory dysfunction, concurrent infection, severe hypoxemia, or those managed in settings with different transplantation pathways and supportive care practices. HRS-AKI trials are also highly sensitive to background albumin administration, timing of therapy, and inclusion criteria, all of which influence response rates.
Nevertheless, the study adds meaningful data to the evolving HRS-AKI treatment landscape. It reinforces the principle that receptor selectivity and controlled vasopressor design may allow safer kidney-directed hemodynamic therapy in cirrhosis. If future trials confirm a durable efficacy signal, OCE-205 could become part of a more nuanced treatment armamentarium that includes terlipressin, norepinephrine in selected settings, albumin, and timely transplant evaluation.
Conclusion
OCE-205 showed a favorable tolerability profile and a numerically higher rate of confirmed clinical improvement in HRS-AKI than placebo, but the phase 2 trial was underpowered and did not demonstrate statistical significance. The most clinically important takeaway is its apparent lack of excess ischemic or respiratory toxicity, a key concern with vasoconstrictor therapy in cirrhosis.
For now, OCE-205 is best interpreted as an encouraging investigational therapy that merits larger, adequately powered studies. Future research should define dose-response relationships, compare OCE-205 directly with established vasoconstrictor regimens, and assess whether its safety advantages translate into clinically meaningful benefits across broader HRS-AKI populations.
Funding and clinicaltrials.gov
The abstract provided does not specify funding details or a clinicaltrials.gov identifier. Readers should consult the full article for sponsor information, protocol specifics, and trial registration data.
References
1. Allegretti AS, Cullaro G, Kwo P, Pyrsopoulos N, Bernstein D, Kjems L, Wong F. OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial. Hepatology (Baltimore, Md.). 2026-04-08. PMID: 41950496.
2. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2021.
3. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of hepatorenal syndrome-acute kidney injury. N Engl J Med. 2021;384:818-828.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460.
AI Image Prompt
High-resolution editorial medical illustration of a hepatology ward focused on hepatorenal syndrome: clinician reviewing kidney function labs and infusion pump next to a patient with cirrhosis, subtle liver and kidney iconography, clean hospital environment, blue-green clinical palette, realistic but polished scientific magazine style.
